Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19, according to data from Phase III trials conducted on 25,800 participants across India. Sources said trial data and results were studied and recommended for approval by the DCGI's Subject Expert Committee on Tuesday. The data was submitted to the DCGI over the weekend.
About Us: NDTV brings you unbiased and comprehensive coverage of news and entertainment programmes in India and abroad. NDTV delivers reliable information across all platforms: TV, Internet and Mobile.
Subscribe to our channels:
NDTV: [ Ссылка ]
NDTV India (Hindi News): [ Ссылка ]
Follow us on Social Media:
Like us on Facebook: [ Ссылка ]
Follow us on Twitter: [ Ссылка ]
Follow us on Instagram: [ Ссылка ]
Join NDTV on Telegram Messenger: [ Ссылка ]
Follow us on Google News for Breaking and Latest News Updates:
NDTV: [ Ссылка ]
NDTV India (Hindi News): [ Ссылка ]
Download NDTV Mobile Apps:
[ Ссылка ]
Watch More Videos:
[ Ссылка ]
#BreakingNews #LatestNews #TodayNews #PoliticalNews #News
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Теги
NDTV 24x7CoronavirusCovid vaccineBharat Biotech's CovaxincovaxinCovaxinPhase 3 TrialCovid VaccineOxford coronavirus vaccineCovid-19Coronavirus VaccineOxford VaccineCovishield VaccineSerum Institutecoronavirus lockdownCoronavirus India UpdatesCoronavirus IndiaCovid-19 CasesCoronavirus India Casesindia coronaviruscovid newssputnik vaccinesputnik 5sputnik vrussian vaccinebharat biotechCoronavirus Updatestv teaserbulletin
